<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572984</url>
  </required_header>
  <id_info>
    <org_study_id>EBUS-TBMCB 2020</org_study_id>
    <nct_id>NCT04572984</nct_id>
  </id_info>
  <brief_title>Transbronchial Mediastinal Cryobiopsy Combined With EBUS-TBNA in the Diagnosis of Mediastinal Lesions</brief_title>
  <official_title>The Study for Diagnostic Value and Safety of Transbronchial Mediastinal Cryobiopsy Combined With EBUS-TBNA in Mediastinal Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study is aimed to investigate the diagnostic efficacy and safety of a novel&#xD;
      less-invasive method, endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy&#xD;
      (EBUS-TBMCB), to sample mediastinal lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A traditional method, endobronchial ultrasound-guided transbronchial needle aspiration&#xD;
      (EBUS-TBNA) and another emerging method, transbronchial forceps biopsy (TBFB) were both used&#xD;
      to be compared. The patients involved were randomly divided into two groups. In the&#xD;
      experimental group, EBUS-TBMCB was performed following EBUS-TBNA while in other two groups,&#xD;
      EBUS-TBNA or EBUS-TBNA and EBUS-TBFB were performed respectively. The samples obtained in the&#xD;
      three groups were analyzed by the pathologists. Patients were followed up for confirming the&#xD;
      diagnosis and complications. The diagnostic accuracy and prevalence of complications were&#xD;
      compared among the three groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnostic sensitivity</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the ratio of the number of diagnosed patients by the diagnostic procedure and the number of all the patients who have undergone this procedure in each arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>complication rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the ratio of the number of patients who had complications caused by the procedure and the number of all the patients who have undergone this procedure in each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sample size</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the area and diameter of sample obtained by each procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>consumed time</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>duration of each period in each procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedure difficulty</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>operator's score on difficulty of each procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sample adequacy</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the ratio of the number of patients with adequate sample by the procedure and the number of all the patients who have undergone this procedure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Mediastinal Lymphadenopathy</condition>
  <arm_group>
    <arm_group_label>EBUS-TBNA-TBMCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was followed by endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy (EBUS-TBMCB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBUS-TBNA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBUS-TBNA-TBFB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was followed by endobronchial ultrasound-guided transbronchial forceps biopsy (EBUS-TBFB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EBUS-TBMCB</intervention_name>
    <description>endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy was performed in experimental arm following EBUS-TBNA</description>
    <arm_group_label>EBUS-TBNA-TBMCB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EBUS-TBFB</intervention_name>
    <description>endobronchial ultrasound-guided transbronchial mediastinal forceps biopsy was performed in experimental arm following EBUS-TBNA</description>
    <arm_group_label>EBUS-TBNA-TBFB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;=15 years;&#xD;
&#xD;
          -  More than one mediastinal lesions with diameter &gt;= 1cm was detected by thoracic CT;&#xD;
&#xD;
          -  Indication of biopsy to identify the etiology, including recently discovered&#xD;
             mediastinal lesions or combination of clinical respiratory symptoms and complicated&#xD;
             lung lesions implicated by thoracic image ;&#xD;
&#xD;
          -  Completion of necessary preoperative laboratory examination;&#xD;
&#xD;
          -  Informed consent form achievement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contradictions to bronchoscopy examination including severe cardio-pulmonary diseases,&#xD;
             coagulation disorders, intolerance to asthenia, etc.;&#xD;
&#xD;
          -  Failure to detect the lesions in ultrasonic landscape within 20 minutes;&#xD;
&#xD;
          -  Indications of high risks to continue the biopsy such as abundant blood flow or&#xD;
             adjacent large vessels detected by ultrasonic landscape.&#xD;
&#xD;
          -  Psychiatric disorders or severe neurosis.&#xD;
&#xD;
          -  Participation in other clinical experiments in recent 3 months;&#xD;
&#xD;
          -  Any other conditions considered to be inappropriate to be involved in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Fan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Military Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felix Herth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik - Heidelberg University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Army Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik - Heidelberg University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-WÃ¼rttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 12, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Ye Fan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphadenopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04572984/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

